A5054962119- Acute Kidney Injury Research
- Melanoma and MAPK Pathways
- Sarcoidosis and Beryllium Toxicity Research
- Eurasian Exchange Networks
- Cardiac Arrest and Resuscitation
- Drug-Induced Adverse Reactions
- Cutaneous Melanoma Detection and Management
- Islamic Thought and Society Studies
- Burn Injury Management and Outcomes
- Cultural and Sociopolitical Studies
Lancashire Teaching Hospitals NHS Foundation Trust
2018
Royal Preston Hospital
2018
University of Birmingham
2014
Pembrolizumab is a programmed cell death protein 1, or PD-1, inhibitor therapy immunotherapy for patients with advanced melanoma. This report discusses series of documented cases sarcoid-like reactions associated this therapy. Three malignant melanoma developed metastatic disease and were treated pembrolizumab immunotherapy. Subsequent imaging showed lymphadenopathy in the mediastinum hilar regions that was confirmed to represent reaction at histologic examination. Radiologists should be...
Acute Kidney Injury (AKI) is a common biochemical finding, however it not always considered as primary diagnosis on admission to hospital when other conditions co-exist. It can have poor prognosis with mortality rates ranging from 10-80%1 .The AKIN criteria give clear guidelines the classification of AKI2 and UK renal association outline investigations that should be carried out3. Table 1: Criteria for Assessing Stage